![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Miravant to Initiate Photrex Confirmatory Phase III Trial in Europe
Miravant to Initiate Photrex Confirmatory Phase III Trial in Europe
Miravant Medical Technologies, a pharmaceutical development company specializing in PhotoPoint photodynamic therapy, plans to conduct a confirmatory Phase III clinical trial for Photrex (rostaporfin, formerly known as SnET2) at investigational sites in Central and Eastern Europe and the UK.
Miravant has selected Kendle, a leading international contract research organization with locations worldwide, to provide clinical development services for the Phase III trial. The randomized, placebo-controlled study, reviewed by the FDA under a special protocol assessment, will evaluate a range of patients with wet age-related macular degeneration, including both classic and occult lesions.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct